FrancophonIA/ELRC3.0 huggingface dataset:
English: The medicine can only be obtained with a prescription.
Estonian: Evicel on retseptiravim.
English: Evicel can also be used in addition to sutures to obtain a watertight closure of the dura mater (a thin fluid-filled membrane surrounding the brain and the spinal cord) during brain surgery.
Estonian: Eviceli tohib kasutada lisaks õmblustele ka selleks, et ajuoperatsioonil sulgeda kõvakest lekkekindlalt.
English: How does Evicel work?
Estonian: Kuidas Evicel toimib?
English: Thromboembolic complications (blood clots) may occur if Evicel is unintentionally injected into a blood vessel.
Estonian: Eviceli juhuslikul süstimisel veresoonde võivad tekkida trombembooliatüsistused (trombid).
English: It can also be used in addition to sutures (stitching) during vascular surgery (surgery on the blood vessels).
Estonian: Eviceli tohib kasutada ka veresoontekirurgias lisaks õmblustele.
English: Avoid contact with eyes.
Estonian: Vältida kontakti silmadega.
English: Cardboard box containing 1 bottle of 76 ml.
Estonian: Pappkarp sisaldab 1 pudelit mahuga 76 ml.
English: This results in minimal amounts to reach the blood stream.
Estonian: Seetõttu on vereringesse jõudvad kogused minimaalsed.
English: QUALITATIVE AND QUANTITATIVE COMPOSITION One ml of solution contains:
Estonian: KVALITATIIVNE JA KVANTITATIIVNE KOOSTIS Üks ml lahust sisaldab: Toimeaine:
English: Spray preferably in a well ventilated area.
Estonian: Pihustada hästi ventileeritud kohas.
English: Allow the application site to dry before permitting contact with such materials.
Estonian: Laske aplitseerimiskohal kuivada enne kokkupuute lubamist selliste materjalidega.
English: DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/).
Estonian: Üksikasjalikku teavet antud veterinaarravimi kohta leiab Euroopa Ravimiameti koduleheküljelt http://www.ema.europa.eu/.
English: In the case of concurrent microbial disease or parasitic infestation, the dog should receive appropriate treatment for such condition.
Estonian: Kaasuva mikroobse või parasitaarse haiguse korral peab koer saama selle seisundi jaoks sobivat ravi.
English: The solvent in this product may stain certain materials including painted, varnished or other household surfaces or furnishings.
Estonian: Selles ravimis sisalduv lahusti võib värvida mõningaid materjale, sealhulgas värvitud, peitsitud või muid majapidamispindu ja mööblit.
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 27/08/2018
Estonian: Esmase müügiloa väljastamise kuupäev: 27/08/2018
English: Since glucocorticosteroids are known to slow growth, use in young animals (under 7 months of age) shall be based on the riskbenefit assessment and subject to regular clinical evaluations.
Estonian: Et glükokortikosteroidid aeglustavad kasvu, peab kasutamine noortel (alla 7 kuu vanustel) koertel toimuma vastavalt kasu-riski hinnangule ja regulaarse kliinilise kontrolli all.
English: This veterinary medicinal product is flammable.
Estonian: See veterinaarravim on tuleohtlik
English: Transient local reactions at the application site (erythema and/or pruritus) can occur in very rare cases.
Estonian: Mööduvad paiksed reaktsioonid manustamiskohas (punetus ja/või sügelus) võivad esineda väga harvadel juhtudel.
English: Manufacturer responsible for batch release: Bioglan AB
Estonian: Partii vabastamise eest vastutav tootja: Bioglan AB
English: Tolerance studies using 3 and 5 times the recommended dosage for twice the recommended duration of treatment resulted in a reduced capacity for production of cortisol that is fully reversible within 7 to 9 weeks after the end of treatment.
Estonian: Taluvusuuringud 3- ja 5-kordse soovitatud annusega kahekordse soovitatud ravikuuri pikkuse puhul põhjustasid kortisooli tootmise võime languse, mis taastus täielikult 7-9 nädala jooksul pärast ravi lõpetamist.
English: Topical application of diesters results in high therapeutic index: high local activity with reduced systemic secondary effects.
Estonian: Diestrite kohalik manustamine tagab kõrge terapeutilise indeksi: suur lokaalne aktiivsus vähenenud süsteemsete kõrvaltoimetega.
English: Do not smoke while handling the veterinary medicinal product.
Estonian: Veterinaarravimi käsitsemise ajal mitte suitsetada.
English: Hydrocortisone aceponate belongs to the diesters class of the glucocorticosteroids.
Estonian: Hüdrokortisoonatseponaat kuulub glükokortikosteroidide diestrite klassi.
English: If signs fail to improve within 7 days, treatment should be re-evaluated by the veterinarian.
Estonian: Kui 7 päeva jooksul paranemist märgata ei ole, tuleks ravi loomaarsti poolt ümber hinnata.
English: The safety of the veterinary medicinal product has not been established during pregnancy and lactation.
Estonian: Veterinaarravimi ohutus tiinuse ja laktatsiooni ajal ei ole tõestatud.
English: Clear colourless to slightly yellow solution.
Estonian: Värvitu läbipaistev kuni kergelt kollane lahus
English: Before administration, screw the pump spray on the bottle.
Estonian: Enne kasutamist keerata pihustipump pudelile.
English: This particularity will increase the ratio between the desired local antiinflammatory effect in the skin and the undesirable systemic effects.
Estonian: See omapära suurendab suhet soovitava lokaalse nahapõletiku vastase toime ja ebasoovitavate süsteemsete kõrvaltoimete vahel.
English: In the absence of information, it is recommended not to apply other topical preparations simultaneously on the same lesions.
Estonian: Andmete puudumise tõttu ei soovitata samaaegselt samadel nahakahjustustel kasutada teisi paikselt manustatavaid ravimeid.
English: The veterinary medicinal product is then applied by activating the pump spray, from a distance of about 10 cm of the area to be treated.
Estonian: Veterinaarravimit manustatakse pumppihusti abil ligikaudu 10 cm kauguselt ravitavast piirkonnast.
English: Hydrocortisone aceponate thus accumulates in the dog's skin allowing local efficacy at low dosage.
Estonian: Hüdrokortisoonatseponaat akumuleerub nii koera nahas, võimaldades lokaalset efektiivsust väikese annusega.
English: Do not spray on naked flame or any incandescent material.
Estonian: Mitte pihustada lahtisele tulele ega hõõguvale materjalile.
English: The diesters are lipophilic components ensuring an enhanced penetration into the skin associated to a low plasma availability.
Estonian: Diestrid on lipofiilsed komponendid, mis tagavad tõhusa tungimise nahka seoses madala biosaadavusega plasmas.
English: PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE BOTTLE (PET)
Estonian: SISEPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED Pudel (PET)
English: Otherwise, use only according to the risk-benefit assessment and subject the dog to regular clinical evaluations.
Estonian: Vastasel juhul kasutada ainult vastavalt kasu-riski hinnangule ja regulaarse kliinilise kontrolli all.
English: Care should be taken to avoid spraying into the eyes of the animal.
Estonian: Hoiduda loomale silma pihustamisest.
English: Use only accordingly to the risk-benefit assessment by the responsible veterinarian.
Estonian: Kasutada ainult vastavalt vastutava veterinaari kasu-riski hinnangule.
English: In laboratory animals, hydrocortisone aceponate is eliminated the same way as hydrocortisone (other name for endogenous cortisol) through urine and faeces.
Estonian: Laboriloomadel elimineerub hüdrokortisoonatseponaat nagu hüdrokortisoongi (teine nimetus endogeensele kortisoolile) uriini ja roojaga.
English: EXP {month/year} Once opened, use within 6 months.
Estonian: EXP Pärast pakendi avamist kasutada ära 6 kuu jooksul.
English: Presented as a volatile spray, this veterinary medicinal product does not require any massage.
Estonian: Antud veterinaarravim on lenduva sprei vormis ja ei vaja nahasse masseerimist.
English: MARKETING AUTHORISATION NUMBER(S) EU/2/18/230/001
Estonian: EU/2/18/230/001
English: Hydrocortisone aceponate applications on the skin lesions provide rapid reduction of the skin redness, irritation and scratching while minimising the general effects.
Estonian: Hüdrokortisoonatseponaat manustamisel nahakahjustustele vähenevad kiiresti nahapunetus, ärritus ja kratsimine, samas kui üldine toime jääb minimaalseks.
English: In case of accidental ingestion, seek medical advice immediately and show the leaflet or the label to the physician.
Estonian: Juhuslikul ravimi allaneelamisel pöörduda viivitamatult arsti poole ja näidata pakendi infolehte või pakendi etiketti.
English: In the absence of specific information, the use in animal suffering from Cushing's syndrome shall be based on the risk-benefit assessment.
Estonian: Täpse teabe puudumisel peab Cushingi sündroomi põdevate loomade ravi põhinema kasu-riski hinnangul.
English: In case of accidental eye contact, rinse with abundant quantities of water.
Estonian: Juhuslikul silma sattumisel loputada rohke veega.
English: In 12 dogs suffering from atopic dermatitis, after topical application on the skin at the recommended therapeutic dosage for 28 to 70 consecutive days, no noticeable effect on the systemic cortisol level was observed.
Estonian: Kaheteistkümnel atoopilise dermatiidiga koeral ei täheldatud pärast paikset manustamist nahale soovitatavas terapeutilises annuses 28…70 päeva jooksul märgatavat mõju süsteemsele kortisoolisisaldusele.
English: MANUFACTURER'S BATCH NUMBER Lot
Estonian: TOOTJAPOOLNE PARTII NUMBER
English: Flammable.
Estonian: Kergestisüttiv.
English: In case of accidental skin contact, wash thoroughly with water.
Estonian: Juhuslikul kokkupuutel nahaga pesta põhjalikult veega.
English: White polyethylene terephthalate (PET) bottle closed with a white polypropylene screw cap with bore seal and supplied with a spray pump.
Estonian: Valge polüetüleentereftalaadi (PET) pudel, mis on suletud polüpropüleenist valge keeratava korgiga, millel on aukudega tihend ja mis on varustatud pihustiga.
English: In case of conditions requiring an extended treatment, the responsible veterinarian should subject the use of the veterinary medicinal product to the risk-benefit assessment.
Estonian: Pikemaajalist ravi nõudvatel juhtudel peab veterinaarravimi kasutamise otsustama vastutav veterinaar vastavalt kasu-riski hinnangule.
English: PSUR submissions shall be synchronised and submitted at the same frequency as for the reference product.
Estonian: Kohta tuleb esitada ravimi perioodiline ohutusaruanne (PSUR) sama sagedusega kui võrdlusravimi puhul.
English: ATC vet code: QD07AC16.
Estonian: Farmakoterapeutiline rühm: Kortikosteroid dermatoloogilised preparaadid ATCvet kood: QD07AC16.
English: In case of eye irritation, seek medical advice.
Estonian: Silmaärrituse tekkimisel pöörduda arsti poole.
English: Hydrocortisone aceponate is a dermocorticoid with a potent intrinsic glucocorticoid activity which means a relief of both inflammation and pruritus leading to a quick improvement of skin lesions observed in case of inflammatory and pruritic dermatosis.
Estonian: Hüdrokortisoonatseponaat on tugeva glükokortikoidse toimega dermokortikoid, mis leevendab nii põletikku kui ka sügelust ja ravib seega kiiresti põletiku ning sügelemisega kulgeva dermatoosi korral tekkinud nahakahjustusi.
English: THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN” Keep out of the sight and reach of children.
Estonian: MÄRGE ”HOIDA LASTE EEST VARJATUD JA KÄTTESAAMATUS KOHAS”
English: Do not use after the expiry date stated on the label.
Estonian: Ärge kasutage veterinaarravimit pärast kõlblikkusaega, mis on märgitud etiketil.
English: Prime the pump before administration.
Estonian: Enne manustamist valmistage ette pump.
English: Do not use on cutaneous ulcers.
Estonian: Mitte kasutada nahahaavandite korral.
English: Bioglan AB Borrgatan 31 211 24 Malmo Sweden
Estonian: SE-21124 Malmö Sweden
English: The diesters are transformed inside the skin structures.
Estonian: Diestrid muunduvad nahastruktuuride sees, mis on selle ravimirühma tõhususe aluseks.
English: For symptomatic treatment of inflammatory and pruritic dermatoses in dogs.
Estonian: Põletiku ja sügelusega kulgeva dermatoosi sümptomaatiliseks raviks koertel.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGE OUTER CARTON
Estonian: VÄLISPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED Välispakend
English: This dosage can be achieved with two pump spray activations over a surface to be treated equivalent to a square of 10 cm x 10 cm. Repeat the treatment daily for 7 consecutive days.
Estonian: Selle annuse saab pumppihusti kahekordse vajutamisega 10 cm x 10 cm ruuduga võrdse ravitava pinna kohal.
English: Systemic absorption of hydrocortisone aceponate being negligible, it is unlikely for teratogenic, foetotoxic, maternotoxic effects to happen at the recommended dosage in dogs.
Estonian: Soovitatavas annuses kasutamisel ei ole teratogeenne, fetotoksiline, maternotoksiline toime koertele tõenäoline, sest hüdrokortisoonatseponaadi süsteemne imendumine on vähene.
English: The recommended dosage is 1.52 µg of hydrocortisone aceponate/cm2 of affected skin per day.
Estonian: Soovitatav annus on 1,52 μg hüdrokortisoonatseponaati cm2 kahjustunud nahapinna kohta.
English: After topical application on the skin at the recommended therapeutic dosage and twice the recommended duration of treatment and at up to a body surface corresponding to the two flanks, from the spine to the mammary chains including the shoulder and the thighs, no systemic effects are observed.
Estonian: Pärast soovitatavas annuses, kuid kaks korda pikema kestusega manustamist looma nahale külgedel selgroost imetiteni (sealhulgas õla- ja reiepiirkonnale) süsteemset toimet ei täheldatud.
English: The veterinary medicinal product contains the active substance hydrocortisone aceponate.
Estonian: Cortavance sisaldab toimeainena hüdrokortisoonatseponaati.
English: Hydrocortisone aceponate administered topically accumulates and is metabolised in skin, as suggested by radioactivity distribution studies and pharmacokinetic data.
Estonian: Radioaktiivsuse jaotumise uuringud ja farmakokineetilised andmed näitavad, et lokaalsel manustamisel akumuleerub ja metaboliseerub hüdrokortisoonatseponaat nahas.
English: Total body surface treated should not exceed a surface corresponding for example to a treatment of two flanks from the spine to the mammary chains including the shoulders and the thighs.
Estonian: Ravitav kehapind ei tohi olla suurem kui looma küljed selgroost kuni imetiteni, sealhulgas õla- ja reiepiirkond.
English: AUTHORISATION
Estonian: KEELUAJAD
English: B-8020
Estonian: 0,584 mg
English: METHOD AND ROUTE(S) OF ADMINISTRATION Cutaneous use.
Estonian: NÄIDUSTUS(ED) MANUSTAMISVIIS JA -TEE(D)
English: SPECIAL STORAGE CONDITIONS Do not store above 25 °C.
Estonian: Hoida temperatuuril kuni 25°C
English: STATEMENT OF ACTIVE SUBSTANCES Each ml contains 0.584 mg of hydrocortisone aceponate.
Estonian: Üks ml sisaldab 0,584 mg hüdrokortisoonatseponaati
English: Pregnancy and lactation:
Estonian: Nahasprei, lahus
English: 4.1 Target species
Estonian: KLIINILISED ANDMED 4.1.
English: Cutaneous use.
Estonian: Nahale manustamiseks.
English: PACKAGE LEAFLET: Cortacare 0.584 mg/ml cutaneous spray solution for dogs
Estonian: PAKENDI INFOLEHT Cortacare 0,584 mg/ml nahasprei lahus koertele
English: NAME OF THE VETERINARY MEDICINAL PRODUCT Cortacare 0.584 mg/ml cutaneous spray solution for dogs hydrocortisone aceponate
Estonian: Cortacare 0,584 mg/ml nahasprei lahus koertele hydrocortisoni aceponas
English: Hydrocortisone aceponate 0.584 mg Equivalent to 0.460 mg of hydrocortisone For the full list of excipients, see section 6.1.
Estonian: Samaväärne 0,460 mg hüdrokortisooniga Abiainete täielik loetelu on esitatud lõigus
English: 10 DATE OF REVISION OF THE TEXT <{MM/YYYY}> <{DD/MM/YYYY}> <{DD month YYYY}>
Estonian: <{Kuu aaaa}> <{pp.kk.aaaa}> <{pp. kuu aaaa}
English: NAME OF THE VETERINARY MEDICINAL PRODUCT Cortacare 0.584 mg/ml cutaneous spray solution for dogs.
Estonian: Cortacare 0,584 mg/ml nahasprei lahus koertele.
English: Specific pharmacovigilance requirements:
Estonian: FARMAKOLOOGILISED OMADUSED
English: CLINICAL PARTICULARS
Estonian: Hüdrokortisoonatseponaat
English: Name and address of the manufacturer responsible for batch release
Estonian: RAVIMIPARTII VABASTAMISE EEST VASTUTAV TOOTJA
English: C. STATEMENT OF THE MRLs Not applicable.
Estonian: C. RAVIMJÄÄKIDE PIIRNORMID
English: The European Commission issued a decision on 6 August 2010.
Estonian: Euroopa Komisjon tegi otsuse 6. augustil 2010.
English: In total, about 9,800 patients have been followed up for six years.
Estonian: Uuringu raames on kuni kuue aasta vältel jälgitud kokku ligikaudu 9800 patsienti.
English: Outcome of a procedure under Article 107 of Directive 2001/83/EC
Estonian: Direktiivi 2001/83/EÜ artikli 107 kohase esilidismenetluse tulemused
English: 1 Afibon, Ectiva, Lindaxa, Meissa, Meridia, Minimacin, Minimectil, Obesan, Sibutral, Sibutril, Siluton, Sitrane, Redoxade, Zelixa and Zelium.
Estonian: 1 Afibon, Ectiva, Lindaxa, Meissa, Meridia, Minimacin, Minimectil, Obesan, Sibutral, Sibutril, Siluton, Sitrane, Redoxade, Zelixa ja Zelium.
English: On the basis of these data, the German medicines regulatory agency (BfArM) triggered in November 2009 a review under Article 107 of Directive 2001/83/EC.
Estonian: Nende andmete alusel algatas Saksamaa ravimiamet (BfArM) 2009. aasta novembris direktiivi 2001/83/EÜ kohase läbivaatamismenetluse.
English: What are the recommendations for prescribers and patients?
Estonian: Millised on soovitused patsientidele ja ravimeid välja kirjutavatele isikutele?
English: The Committee also asked the company to provide six-monthly updates on the progress of the study.
Estonian: Samuti palus komitee ettevõttel esitada iga kuue kuu tagant teavet uuringu edenemise kohta.
English: What is sibutramine?
Estonian: Mis on sibutramiin?
English: The European Medicines Agency has completed a review of the safety and effectiveness of sibutramine.
Estonian: Euroopa Ravimiamet on lõpetanud sibutramiini ohutuse ja efektiivsuse läbivaatamise.
English: They are available as capsules containing 10 mg or 15 mg sibutramine, under the trade names Reductil and other names1, and as generic medicines.
Estonian: Neid turustatakse 10 mg või 15 mg sibutramiini sisaldavate kapslitena Reductili ja teiste kaubanduslike nimetuste1 all ning geneeriliste ravimitena.
English: The CHMP reviewed the responses from the company to a list of questions on the SCOUT study.
Estonian: Inimravimite komitee vaatas läbi ettevõtte vastused küsimustele uuringu SCOUT kohta.
English: Sibutramine-containing medicines have been authorised in the European Union (EU) since 1999.
Estonian: Sibutramiini sisaldavatel ravimitel on Euroopa Liidus müügiload alates 1999. aastast.
English: They are used, alongside diet and exercise, in patients who are obese (very overweight) with a body mass index (BMI) greater than or equal to 30 kg/m², and in patients who are overweight (with a BMI greater than or equal to 27 kg/m²) and also have other obesity-related risk factors, such as type 2 diabetes or dyslipidaemia (abnormal levels of fat in the blood).
Estonian: Sibutramiini sisaldavaid ravimeid kasutatakse koos dieedi ja füüsilise koormusega rasvunud (väga suure ülekaaluga) patsientidel, kelle kehamassi indeks on vähemalt 30 kg/m², ning ülekaalulistel patsientidel, kelle kehamassi indeks on vähemalt 27 kg/m² ja kellel esineb ka muid rasvumisega seotud ohutegureid, näiteks II tüüpi diabeet või düslipideemia (vere ebaharilikult suur rasvasisaldus).
English: Although the full data from the SCOUT study have not yet been analysed, the study's Data Safety Monitoring Board (a body of independent experts appointed to review regularly the outcome of the clinical trial) informed the Agency in October 2009 of preliminary data indicating that sibutramine is associated with more cardiovascular problems than placebo.
Estonian: Kuigi kõiki uuringu SCOUT andmeid ei ole veel analüüsitud, teavitas uuringu andmeohutuse jälgimise nõukogu (koosneb sõltumatutest ekspertidest, kelle ülesanne on kliinilise uuringu tulemuste korrapärane hindamine) ravimiametit 2009. aasta oktoobris sellest, et esialgsete andmete kohaselt esineb sibutramiiniga kardiovaskulaarseid probleeme rohkem kui platseeboga.
English: The Committee also looked at other studies on the effectiveness of sibutramine for weight loss.
Estonian: Samuti arutas komitee teisi uuringuid sibutramiini efektiivsuse kohta kehakaalu vähendamisel.
English: By blocking their re-uptake, sibutramine increases the amount of these neurotransmitters in the brain.
Estonian: Nende tagasihaarde inhibeerimisega suurendab sibutramiin neurotransmitterite arvu peaajus.
English: The increased levels of neurotransmitters in the brain help patients to feel full after a meal, and this helps to reduce their food intake.
Estonian: Kuna neurotransmitterite arv peaajus on suurem, tekib patsientidel pärast söömist hõlpsamini täiskõhutunne ning see aitab vähendada manustatava toidu kogust.
English: The suspension will remain in place until the company can provide data that are sufficient to allow the identification of a group of patients for whom sibutramine's benefits clearly outweigh its risks.
Estonian: Müügiload on peatatud seni, kuni ettevõte esitab andmed, mis võimaldaks välja selgitada patsiendirühma, kellel on sibutramiini kasulikkus selgelt suurem kui sellega kaasnevad riskid.
English: • Pharmacist should no longer dispense sibutramine-containing medicines.
Estonian: • Apteekrid ei tohi sibutramiini sisaldavaid ravimeid enam väljastada.
English: Questions and answers on the suspension of medicines containing sibutramine
Estonian: Teave sibutramiini sisaldavate ravimite müügilubade peatamise kohta
English: Sibutramine is a ‘serotonin-noradrenaline re-uptake inhibitor' (SNRI).
Estonian: Sibutramiin on serotoniini ja noradrenaliini tagasihaarde inhibiitor.
English: They requested that the CHMP assess the impact of the new data on the benefit-risk balance of sibutramine to prepare an opinion on whether the marketing authorisations for products containing sibutramine should be maintained, changed, suspended or withdrawn across the EU.
Estonian: Inimravimite komiteel paluti hinnata, kuidas mõjutavad uued andmed sibutramiini kasulikkuse ja sellega kaasnevate riskide suhet ning esitada oma arvamus selle kohta, kas sibutramiini sisaldavate ravimite müügiload tuleks ELis säilitada, peatada, tagasi võtta või tuleks neid muuta.
English: The Committee also consulted a group of experts specialising in the treatment of metabolic diseases.
Estonian: Peale selle pidas komitee nõu ainevahetushaigustele spetsialiseerunud ekspertidega.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that the benefits of sibutramine do not outweigh its risks, and that all marketing authorisations for medicines containing sibutramine should be suspended throughout Europe.
Estonian: Ravimiameti inimravimite komitee jõudis järeldusele, et sibutramiini kasulikkus ei ole suurem kui sellega kaasnevad riskid ning et kõik sibutramiini sisaldavate ravimite müügiload tuleb kogu Euroopas peatada.
English: The Committee also noted that it is not clear if this effect on weight loss can be maintained when sibutramine treatment is stopped.
Estonian: Samuti märkis komitee, et ei ole selge, kas kehakaal väheneb ka pärast sibutramiiniravi lõpetamist.
English: Why was sibutramine reviewed?
Estonian: Mis oli sibutramiini läbivaatamise põhjus?
English: • Patients who are taking a medicine containing sibutramine to help them to lose weight should make an appointment with their doctor at the next convenient time to discuss alternative measures to lose weight.
Estonian: • Kehakaalu langetamiseks sibutramiini sisaldavaid ravimeid võtvad patsiendid peaksid sobival ajal pöörduma oma arsti poole, et arutada muid viise kehakaalu langetamiseks.